Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACCEPT study of acalabrutinib with R-CHOP in untreated diffuse large B-cell lymphoma
ISRCTN13626902Phase 2Completed
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- Apr 2017
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of acalabrutinib in diffuse large B-cell lymphoma (DLBCL) (3 arms), sponsored by University Hospital Southampton NHS Foundation Trust. Primary endpoints: Dose-limiting toxicity, Overall response rate and 1 more. Started Apr 2017; status: completed.
02
Drugs
acalabrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ISRCTN13626902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN13626902.